Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of NNC0480-0389 + Semaglutide in Healthy Japanese Men
NCT04878406Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- May 2021
- Primary completion
- Jul 2021
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NNC0480-0389 in type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Novo Nordisk. Primary endpoint: Number of treatment emergent adverse events. Started May 2021; status: completed.
02
Drugs
NNC0480-0389
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04878406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04878406.